Who Pays for a Longer Life?
Imagine a treatment that costs $2 million. It sounds outrageous.
Now imagine that the treatment is given once and prevents 30 years of hospital visits, medications, disability and lost work. Suddenly, $2 million becomes harder to judge.
This is the strange economics biotechnology is beginning to create.
For most of modern medicine, the business model was simple: you become sick, someone treats you, and someone pays. But what happens when medicine can potentially remove a disease for years — or one day give us additional years of healthy life?
The question stops being only “Does it work?”
It becomes:
Who pays for the extra time?
The $2 Million Medicine
We already have a real-world experiment.
Casgevy, the CRISPR-based therapy for sickle cell disease discussed earlier in this series, entered the U.S. market with a list price of about 2.2millionperpatient.Anothergenetherapy,Lyfgenia,waslistedat3.1 million.
Those are extraordinary numbers. But so is the disease they treat.
More than 100,000 Americans live with sickle cell disease. Patients can experience repeated pain crises, hospitalizations, strokes and organ damage. Life expectancy can be more than 20 years shorter than for people without the disease.
Hospitalizations and other serious health episodes associated with sickle cell disease cost the U.S. healthcare system almost $3 billion every year.
So which number should frighten us? $2.2 million today? Or decades of medical costs tomorrow?
There is no simple answer. Gene therapy also requires expensive specialized care, and we do not yet have decades of evidence proving exactly how durable every benefit will be.
But biotechnology is forcing healthcare systems to think differently about time.
The Patient Is Not the Buyer
There is another complication.
Most people do not have $2 million. They do not have $200,000 either.
So the person receiving an advanced therapy is usually not the person making the economic decision.
The real buyer may be an insurance company, an employer or a government.
In sickle cell disease this becomes particularly striking. Roughly 50–60% of Americans with the condition are covered by Medicaid.
That means a technology developed by private biotechnology companies can ultimately present a multimillion-dollar invoice to taxpayers.
And governments have a problem.
A $2 million treatment might save money over 30 years.
A state budget operates one year at a time.
This is one of the great mismatches of modern medicine:
the biology is long-term, but the budget is short-term.
What If We Pay Only When It Works?
One answer is beginning to emerge.
Don't simply buy the drug. Buy the result.
The U.S. Centers for Medicare & Medicaid Services created the Cell and Gene Therapy Access Model for exactly this problem. It negotiated agreements under which participating Medicaid programs receive discounts and can receive additional rebates if the therapies fail to deliver specified health benefits.
The program now has 34 state participants, while the broader set of participating jurisdictions announced in 2025 represented about 84% of Medicaid beneficiaries with sickle cell disease.
Think about what has happened. Medicine has become a financial contract on future health.
The manufacturer is no longer saying only:
Here is the treatment.
The payer can effectively answer:
Fine. But if the patient does not get the promised benefit, you give some of the money back.
That logic could become much more important as biotechnology moves from drugs taken every day toward interventions intended to work for years.
Then Longevity Makes Everything More Complicated
Now take the idea one step further.
Suppose biotechnology eventually produces a treatment that does not cure one rare disease but delays several diseases of aging.
It does not make you immortal. It simply gives the average 65-year-old five additional healthy years.
Who should pay?
An insurer might hesitate. The customer could switch insurance companies next year, while the benefits appear decades later.
An employer has the same problem. A government might have the strongest incentive because healthier citizens could mean lower medical and disability costs.
But government would also face the opposite consequence. People who live longer may collect pensions longer.
And individuals? A wealthy 60-year-old might happily pay $100,000 for five additional healthy years. A schoolteacher with $8,000 in savings might not have that option.
This is where longevity stops being merely a medical story.
It becomes a distribution problem.
When Time Becomes Something Money Can Buy
Money has always influenced health.
Rich people generally have better access to nutrition, safer environments, specialists, preventive medicine and high-quality care.
So inequality in health is hardly new.
But biotechnology could create a more unsettling version of it.
Imagine that by 2045 a therapy can reliably delay age-related disease by five years. The exact technology does not matter.
Suppose it costs $500,000. For the wealthy, this becomes another expensive asset. A house. A portfolio. An education for the children. And five more healthy years.
For everyone else, it becomes something to argue about with an insurance company.
We would have crossed an unusual line. For most of history, wealth could buy a more comfortable life.
Now it might begin to buy more healthy time itself.
The Most Expensive Treatment May Be the Cheapest One
And here is the paradox.
The biotechnology revolution may produce some of the most expensive medicines ever created. Yet some could eventually reduce the total cost of healthcare.
A therapy costing $1 million looks absurd when compared with a $20 prescription. But the comparison is wrong if the $20 prescription must be taken for decades, alongside hospital visits, surgeries, nursing care and lost productivity.
The economically relevant question is not:
How expensive is the treatment?
It is:
What does the world without the treatment cost?
That is much harder to calculate.
And it explains why the future of biotechnology will be shaped not only in laboratories.
It will also be shaped by insurers, pension systems, government budgets and spreadsheets.
The Real Longevity Question
People like asking how long humans might eventually live.
100? 120? 150?
But perhaps economics will determine the answer before biology does.
The first truly effective longevity therapy will create an extraordinary medical question.
It will also create a much less glamorous one:
Who gets it?
If biotechnology succeeds, the great achievement of the coming decades may not be immortality. It may be five or ten additional years in which people can work, travel, think clearly, live independently and carry their own suitcase.
Science may eventually learn how to produce those years. Then society will have to decide how to pay for them.
Because the most valuable product biotechnology may ever create is not a drug.
It is time.